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Introduction
The vascular endothelium lines the entire inner surface of all 
blood vessels and forms specific barriers in different organs to 
regulate vascular permeability. The blood-brain barrier (BBB) 
represents one such barrier and prevents the leakage of blood-
borne substances into brain parenchyma. Disruption of the BBB 
characterised by the formation of brain oedema is a common 
occurrence after ischaemic strokes and constitutes the main 
cause of mortality within the first week after a cerebrovascular 
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Abstract
Title: Suppression of protein kinase C-α ameliorates hyperglycaemia-evoked in 
vitro cerebral barrier dysfunction. 
Background: Ischaemic stroke is common in diabetes patients and occurs due to 
cerebral-barrier dysfunction. Although the pathological activation of protein kinase 
C (PKC) is linked with the disease progression, the PKC isoform-specific downstream 
signalling remains obscure and is the focus of this study which explored the clinical 
relevance of PKC-α inhibitor Ro-32-0432 under hyperglycaemia (HG). 
Methods and Findings: Total PKC and RhoA activities were studied in human brain 
microvascular endothelial cells (HBMEC) exposed to normoglycaemia or HG. The 
integrity and function of an in vitro model of human BBB composed of HBMEC and 
human astrocytes were measured by transendothelial electrical resistance (TEER) 
and paracellular flux of Evans blue-labelled albumin (EBA), respectively. Exposure 
of HBMEC to HG for 72 hours led to significant increases in activities of total PKC 
and RhoA as well as in mono- and di-phosphorylation of MLC2 which concurred 
with substantial decreases in TEER and marked elevations in barrier permeability. 
Enhanced cellular contractility triggered by actin stress fibre formation appeared to 
further potentiate HG-mediated barrier dysfunction. Pre-treatment of HBMEC with 
Ro-32-0432 or transient PKC-α protein knockdown led to effective preservation of 
BBB integrity and function in hyperglycaemic settings by suppressing RhoA activity 
and subsequently normalising the MLC2 phosphorylation on Ser19 and Thr18-
Ser19 residues. These observations were further supported by disappearance of 
stress fibres and subsequent restoration of the cortical actin staining.
Conclusions: Neutralisation of PKC-α activity may be of considerable therapeutic 
value in clinical settings accompanied by diabetes or stress HG. 
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attack. As the brain oedema is more prevalent in stroke patients 
with diabetes mellitus, it is thought that hyperglycaemia may be 
intricately involved in the pathogenesis of this defect [1-3].
The BBB consists of brain microvascular endothelial cells (BMEC), 
capillary basement membrane and astrocyte end-feet supporting 
the basement membrane. The permeability of the BBB is 
tightly regulated by tight junction proteins, notably occludin 
and claudin-5, that exist between the adjacent BMEC. Hence, 
pathologies that affect BMEC phenotype and/or tight junction 
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effect on the integrity and function of the BBB. Although several 
biochemical pathways including non-enzymatic glycation of 
proteins and lipids with the irreversible deposition of advanced 
glycation end products, the activation of polyol pathway or 
stimulation of protein kinase C (PKC) pathway have been 
implicated in diabetes-mediated peripheral vasculopathies, the 
mechanisms involved in hyperglycaemia-evoked cerebrovascular 
impairments remain largely unknown [4].
In addition to regulation of PKC activity, the suppression of RhoA 
may also be an efficacious therapeutic option in protecting 
cerebral barrier integrity given the fact that binding of active 
RhoA to its downstream effector Rho-kinase leads to the 
disruption of intercellular junctions by sequential induction of 
myosin-regulatory light chain-2 phosphorylation (pMLC2) and 
actin stress fibre formation [5-16].
In light of the above, this study investigated the specific role of 
PKC-α isoform in hyperglycaemia-mediated cerebral damage 
using an in vitro model of human BBB. In addition, comprehensive 
analyses of the relationship between PKC-α isoform and RhoA/
pMLC2 pathway were performed to unravel new therapeutic 
targets that can be utilised to prevent or minimise cerebral 
barrier damage in hyperglycaemic settings. 
Material and Methods 
Cell culture 
Human BMEC (HBMEC) and astrocytes (HA) were purchased 
from TCS CellWorks, UK and cultured up to passage 6 in their 
respective specialised medium in humidified atmosphere 
under normal conditions (70% N2, 25% O2 and 5% CO2 at 37°C) 
before exposure to normoglycaemia (5.5 mM D-glucose) or 
hyperglycaemia (25 mM D-glucose) for 72 hours. The significance 
of changes in PKC-α activity to HG-mediated endothelial-barrier 
damage was assessed using a specific inhibitor, Ro-32-0432 (1-5 
µM). In a subset of experiments, HBMEC were initially cultured 
in hyperglycaemic conditions for 72 hours before a further 72 
hours culture in normoglycaemic conditions to assess the specific 
effects of glucose normalisation (glycaemic control). Cells were 
also cultured in equimolar concentrations of D-mannitol (25 mM) 
to assess if the changes observed in enzyme activities and BBB 
integrity were due to hyperosmolality rather than HG per se. 
In vitro model of human BBB
HA were seeded on the outside of polyester membrane (0.4 
µm pore size) transwell inserts (Corning Costar, High Wycombe, 
UK) directed upside down in the 6-well tissue culture plates. 
Following the overnight adherence of HA to the membranes, 
the inserts were inverted the correct way in the 12-well tissue 
culture plates and HBMEC were seeded onto the inner side of 
the polyester membrane. The cells were cultured to confluence 
before exposing co-cultures to the experimental conditions.
BBB experiments
The integrity and function of human BBB were assessed by 
measurements of transendothelial electrical resistance (TEER) 
and the flux of Evan’s blue-labelled albumin (EBA), a high 
molecular weight permeability marker (67 kDa), across the co-
cultures as previously described [17].
Immunoblotting
 To evaluate the fold differences in protein levels, immunoblottings 
were performed [15] using the specific antibodies raised against 
total RhoA, total MLC2, pMLC2-Ser19, pMLC2-Thr18-Ser19, 
PKC-α, PKC-β (Santa Cruz Biotech) and β-actin (Sigma-Aldrich, 
UK).
Immunofluorescence
HBMEC cultured on 8-chamber tissue slides (Lab-Tek) were fixed 
and permeabilised with 4% paraformaldehyde/PBS and 0.1% 
Triton X-100/PBS, respectively for 20 min each before visualising 
actin cytoskeleton via Rhodamine-labelled phalloidin dye (5 U/
mL, Invitrogen, UK). The cells were stained with 4,6-diamidino-
2-phenylindole to visualise the nuclei and viewed under 40X 
magnification on a Zeiss Axio Observer fluorescence microscope 
(Germany).
Rho activity assay
The RhoA activity was measured using a “pull-down” assay kit 
(Millipore, UK). Briefly, about 150 µg of HBMEC lysates were 
incubated with Rhotekin Rho-binding peptide immobilized on 
agarose beads (10 µg) prior to detection of activated guanosine 
triphosphate-RhoA bound to Rhotekin by immunoblotting.
PKC activity assay
Total PKC activity was determined in HBMEC lysates as previously 
described using the non-radioactive PKC activity assay kit 
(Promega, UK) which utilises a brightly coloured PKC-specific 
peptide substrate, PepTag C1 [17].
Transient knockdown
To knockdown PKC-α protein expression, semi-confluent 
HBMEC were transfected for 24 hours with DharmaFECT siRNA 
transfection reagent-4 containing 50 nM of either ON-TARGET 
plus non-targeting pool of small interfering RNA (siRNA) or 
ON-TARGET plus SMART pool human siRNA against PKC-α (GE 
Dharmacon). Following first round of transfection, the cells were 
allowed to recover in the fresh medium for 6 hours before second 
round of transfection with 50 nM of aforementioned siRNA 
molecules. The cells were homogenised after 72 hours to assess 
the downregulation of protein expression by immunoblotting.
Assessment of cell viability
A fraction of cells exposed to different treatments were incubated 
with 0.1% trypan blue for 5 minutes and the percentages 
of cell viability were calculated by counting 100 cells on a 
haemocytometer under light microscope.
Statistical Analysis
Statistical analyses were performed using IBM SPSS statistics 21.0 
software package. The mean values were compared by Student’s 
two-tailed t-test or one-way ANOVA, where appropriate, followed 
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Results
Inhibition of PKC-α protects BBB integrity and 
function under hyperglycaemic conditions
Using an in vitro model of human BBB established by co-culture 
of HBMEC and HA, we have recently shown that inhibition of total 
PKC with Bis-I negates the deleterious effects of hyperglycaemia 
on BBB integrity [14]. The present study shows that specific 
attenuation of PKC-α activity by Ro-32-0432 also normalises the 
disruptive effects of hyperglycaemia on cerebral barrier structure 
and function (Figure 1A-B).
PKC-α modulates the activation of RhoA signalling 
in hyperglycaemic settings
Since overactivities of PKC and RhoA have previously been 
implicated in cerebral barrier dysfunction [15,17-19] and Ro-
32-0432 effectively maintains barrier integrity and function in 
hyperglycaemic settings, it is possible that inhibition of PKC-α may 
protect BBB by concomitantly regulating the activities of total 
PKC and RhoA. Indeed, inhibition of PKC-α reduces the total PKC 
activity in HBMEC below the levels seen in cells exposed to equal 
periods of hyperglycaemia, normoglycaemia or hyperglycaemia 
followed by normoglycaemia (Figure 2). Moreover, inhibition 
of PKC-α normalised the hyperglycaemia-mediated increases 
observed in RhoA-GTP protein levels, a measure of RhoA activity 
without affecting that of total RhoA (Figure 3A). In support of this, 
attenuation of PKC-α gene expression by a specific siRNA appeared 
to diminish RhoA-GTP protein levels without affecting total RhoA 
levels in HBMEC exposed to normoglycaemia and hyperglycaemia. 
In these experiments, suppression of the basal RhoA activity in 
normoglycaemic cells by PKC-α siRNA confirmed the efficacy of 
this experimental procedure (Figure 3B). Moreover, the inefficacy 
of PKC-α siRNA to affect PKC-β protein expression confirmed the 
specificity of the siRNAs employed for PKC-α (Figure 3C,D).
PKC-α mediates hyperglycaemia-evoked cytoskel-
etal remodelling
Cytoskeletal reorganisation induced by activation of RhoA has 
previously been coupled to enhanced cerebral barrier permeability 
[15,17,19]. To evaluate whether barrier-protective effects of PKC-α 
inhibition may in part be attributed to its modulatory effects on 
endothelial cell cytoskeletal proteins MLC2 and F-actin, this study 
examined the effects of hyperglycaemia on MLC2 mono- and 
di-phosphorylation levels and F-actin cellular localisation in the 
absence or presence of Ro-32-0432. While hyperglycaemia alone 
evoked a dramatic increase in the protein levels of pMLC2-Ser19 and 
pMLC2-Thr18/Ser19, co-treatment with Ro-32-0432 suppressed 
both phosphorylation rates in a dose-dependent manner without 
altering the total MLC2 levels (Figure 4A-B). In addition to this, 
hyperglycaemia promoted the formation of stress fibres traversing 
the cells. However, co-treatments with Ro-32-0432 eradicated stress 
fibres and restored cortical actin localisation similar to those seen in 
normoglycaemic cells (Figure 4C). Silencing of PKC-α expression in 
normoglycaemic and hyperglycaemic HBMEC via siRNA technology 
fully corroborated these results (Figure 5A-C).
Effects of glucose normalisation and osmolality 
on enzyme activities and BBB integrity
Hyperglycaemia-induced increases observed in total RhoA activity 
and impairments in BBB integrity and function were independent 
of a rise in osmolality as ascertained by application of equal 
concentrations of D-mannitol (25 mM) and were completely 
neutralised by normalisation of glucose levels (Table 1).
Discussion
hyperglycaemia stemming from an imbalance in glucose 
metabolism adversely affects vascular homeostasis and 
exacerbates the intensity of vasculopathies, notably endothelial 
dysfunction commonly encountered in patients with history 
Figure 1 Effects of normoglycaemia (D-glucose 5.5mM) and 
hyperglycaemia (D-glucose 25 mM) on an in vitro 
model of human blood-brain barrier integrity and 
function in the absence or presence of a specific 
inhibitor for PKC-α, Ro-32-0432 (5 μM), as assessed 
by measurements of transendothelial electrical 
resistance (TEER) (A) and EBA flux (B), respectively. 
Data are expressed as mean ± SEM from 4 independent 
experiments. *P<0.05 compared to normoglycaemia, 
†P<0.05 compared to hyperglycaemia.
Figure 2 Effects of normoglycaemia (D-glucose 5.5 mM), 
hyperglycaemia (D-glucose 25 mM), osmolality 
(D-mannitol 25 mM), normalisation of glucose levels 
after hyperglycaemia and hyperglycaemia with Ro-
32-0432 (5μM) on total protein kinase C (PKC) activity 
(Units/mL) in human brain microvascular endothelial. 
Mean ± SEM from 4 independent experiments. *P<0.05 
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of myocardial infarction and stroke. Although endothelial 
dysfunction in cerebral vasculature is intimately associated with 
the initiation and/or progression of BBB failure, the molecular 
mechanism(s) involved remains largely unknown. Using an in 
vitro model of human BBB composed of HBMEC and astrocytes, 
the current study reveals PKC-α as an important component in 
hyperglycaemia-mediated BBB dysfunction. Activation of PKC-α 
has been shown to enhance the levels of small GTP-binding protein, 
RhoA which in turn successively modulates phosphorylation and 
localisation of cytoskeletal proteins, namely MLC2 and actin 
microfilaments and as a consequence promote cytoskeletal 
reorganisation and BBB leakage. Inhibition of PKC-α activity under 
Figure 3 Effects of normoglycaemia (D-glucose 5.5 mM) and hyperglycaemia (D-glucose 25 mM) alone or in the presence of a PKC-α 
inhibitor Ro-32-0432 (5 μM) on total RhoA activity (A). Effects of non-targeting and PKC-α specific siRNA molecules on the 
total RhoA activity (B), protein expressions of PKC-α (C), PKC-β (D) in human brain microvascular endothelial cells exposed to 
normoglycaemia or hyperglycaemia. Data are expressed as mean±SEM from 3 independent experiments. *P<0.05 compared to 
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hyperglycaemic conditions by Ro-32-0432 or PKC-α siRNA appear 
to alleviate cytoskeletal remodelling and improve endothelial 
barrier integrity and function by normalising the RhoA activity. 
Repetition of similar experiments with equimolar concentration 
of D-mannitol (25 mM) overtly indicates that these changes were 
independent of an increase in osmolality, in keeping with the 
findings of our previous studies [14,17]. In addition, normalisation 
of glucose levels after a period of hyperglycaemic insult (72 hours) 
appeared to mitigate the effects of hyperglycaemia on total PKC 
and RhoA activities and on cerebral-barrier integrity, indicating 
Figure 4 Dose-dependent effect of Ro-32-0432 on MLC2 mono-phosphorylation (A), di-phosphorylation (B) and F-actin staining (C) in human 
brain microvascular endothelial cells exposed to normoglycaemia (D-glucose 5.5mM) or hyperglycaemia (D-glucose 25mM) with/
without PKC-α inhibitor Ro-32-0432 (5μM). Arrows indicate stress fibre formations. Scale bar: 50 μm. Data are expressed as mean ± 
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the importance of effective glycaemic control. Indeed, while 
poor glycaemic control in patients with type 2 diabetes has 
been positively correlated with an elevated plasma level 
of vascular endothelial growth factor and development of 
diabetic retinopathy, its effective regulation, confirmed by 
decreases in gylcated haemoglobin (HbA1c) levels, appeared to 
prevent the progression of diabetic retinopathy [20]. Similarly, 
efficacious management of hyperglycaemia in streptozotocin-
diabetes rats has been shown to enhance the expression of an 
endoprotective transcription factor, Kruppel-like factor 2 and 
attenuate proteinuria, glomerular hypertrophy and endothelial 
injury, hallmarks of diabetic nephropathy [21].
Considering that PKC regulates a wide range of activities 
individually or collectively associated with endothelial 
Figure 5 Effects of non-targeting and PKC-α specific siRNA molecules on MLC2 mono-phosphorylation (A), di-phosphorylation (B) and F-actin 
staining (C) in human brain microvascular endothelial cells exposed to normoglycaemia (D-glucose 5.5 mM) or hyperglycaemia 
(D-glucose 25mM). Arrows indicate stress fibre formations. Scale bar: 50 μm. Data are expressed as mean ± SEM from 3 independent 
experiments. *P<0.05 compared to normoglycaemia, †P<0.05 compared to hyperglycaemia. 
(dys) function like excessive production of reactive oxygen 
species, cytokines, growth factors and the activation of matrix 
metalloproteinases [5], it was of no surprise that treatments 
with Ro-32-0432 (1-5 μM), an inhibitor of PKC-α restored BBB 
integrity and function under hyperglycaemic conditions in a dose-
dependent manner. The concentrations of Ro-32-0432 employed 
in this study were in the previously reported working range (1-10 
μM) and did not markedly affect HBMEC viability similar to human 
lung epithelial cells, platelets and monocytes [22-24]. As 5 μM of 
Ro-32-0432 diminished RhoA-GTP activity to the levels obtained by 
silencing of PKC-α gene via its siRNA, this dose was used during the 
rest of the study.
Exposure of HBMEC to hyperglycaemia potentiated the activity 
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below the levels observed in normoglycaemic cells, implying 
effective neutralisation of both basal and induced levels of 
PKC-α activity with this particular inhibitor. These results 
suggest that activation of PKC-α significantly contributes to the 
enhanced overall PKC activity and ensuing vascular pathologies 
in hyperglycaemic conditions. Indeed, activation of PKC-α in 
diabetic rats has been shown to enhance the NADPH oxidase-
mediated superoxide production in renal tissues and elevate 
the renal, serum, and urinary vascular endothelial growth factor 
concentrations leading to diabetic nephropathy [25]. Similarly, 
activation of PKC-α has been coupled to increased incidence 
of heart failure in mice where its effective inhibition improved 
ventricular performance and reduced fibrosis and pulmonary 
oedema [26].
Similar to total PKC, exposure of HBMEC to hyperglycaemia 
also resulted in an increase in RhoA activity. Like PKC, small 
GTPase RhoA is also implicated in various processes that can 
radically affect the integrity and permeability of the BBB. 
Once activated, RhoA has been shown to bind to its effector 
protein Rho-kinase and promote stress fibre formation and 
MLC2 phosphorylation which in turn increase paracellular flux 
by destabilising cell junctions thereby suggesting the notion 
that inhibition of RhoA may be of paramount importance in 
attaining normal microvascular function and negating barrier 
permeability [15,27,28]. Indeed, inhibition of Rho-kinase activity 
by Y-27632 has been shown to completely abolish these effects 
in different conditions known to affect BBB integrity including 
hyperglycaemia and oxygen-glucose deprivation alone or followed 
by reperfusion [15,17]. In accordance with these findings, in the 
current study hyperglycaemia has been shown to trigger MLC2 
phosphorylation and cytoskeletal reorganisation characterised 
by appearance of thick actin stress fibres traversing the cells. 
Interestingly, inhibition of PKC-α activity by Ro-32-0432 in HBMEC 
mimicked the endothelial-barrier protective effects of Y-27632 by 
normalising the RhoA activity, mono- and di-phosphorylation of 
MLC2, reducing stress fibre formations and restoring the F-actin 
localisation to the cellular cortex [17]. These results indicate that 
PKC-α can effectively modulate the RhoA/Rho-kinase signalling 
pathway. The importance of this pathway has been exemplified 
in a recent study with retinal pigment epithelial cells where PKC-α 
overactivity is associated with enhanced cell migration triggered 
by the formation of stress fibres and actin cytoskeletal remodelling 
contributing to the development of proliferative eye diseases 
[29]. Furthermore, in vivo studies with mice and in vitro studies 
with human pulmonary artery endothelial cells have also shown 
that activation of PKC-α with microtubule-disrupting agents like 
2-methoxyestradiol increase endothelial-barrier permeability 
by phosphorylating ezrin, radixin and moesin proteins, known 
to activate the Rho signalling and promote de novo assembly of 
F-actin [30-32].
In addition to its effects on cellular architecture, activation of 
RhoA also affects localisation of occludin and zonula occludens-1, 
Table 1: Hyperglycaemia-induced increases observed in total RhoA activity and impairments in BBB integrity and function were independent of a 
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tight junction proteins that prevent paracellular leakage [17]. 
Besides, RhoA activation potentiates the activities of matrix 
metalloproteinases which digest extracellular matrix components 
and thus enhance endothelial-barrier permeability [33]. Since 
Ro-32-0432 may also interfere with the activities of PKC-β 
[23,34], the specific relevance of PKC-α to RhoA activity, MLC2 
phosphorylation and cytoskeletal remodelling in hyperglycaemic 
settings was investigated in HBMEC after silencing its gene 
expression by siRNAs which had no effect on PKC-α protein 
expression thereby confirming specificity. The results generated 
were similar to those obtained with Ro-32-0432, confirming the 
regulatory role of PKC-α in RhoA activation and supporting the 
previous studies showing PKC-α-mediated activation of RhoA 
at cell membrane by either regulating its dissociation from 
Rho guanine dissociation inhibitor 1-RhoA complex to promote 
its cytoplasmic trafficking as seen in pancreatic acini or by 
phosphorylating p115Rho guanine exchange factor to facilitate 
the exchange of GDP with GTP as reported in mouse BMEC 
[35]. Along with promoting cytoskeletal remodelling, enhanced 
PKC-α activity may also compromise endothelial barrier integrity 
by inducing apoptosis, matrix metalloproteinase activity or 
oxidative stress through modulating the excessive synthesis of 
reactive oxygen species, in particular, superoxide anion by pro-
oxidant enzyme NADPH oxidase and/or suppressing nitric oxide 
availability, a key regulator of vascular homeostasis by uncoupling 
endothelial nitric oxide synthase (eNOS) [36,37]. Hence, selective 
inhibition of conventional PKC isoforms in type 2 diabetic rats by 
Ro-32-0432 and Go-6976 have been shown to mitigate oxidative 
stress in conduit arteries by both restoring eNOS function and 
attenuating NADPH oxidase hyperactivity [38,39]. Furthermore, 
siRNA-mediated inhibition of PKC-α in HBMEC neutralised the 
barrier-disruptive effects of oxygen-glucose deprivation and 
TNF-α, an inflammatory cytokine by attenuating oxidative stress, 
apoptosis and the activity of basement membrane-degrading 
enzymes [40]. 
It is noteworthy here that both normalisation of glucose levels and 
targeted silencing the activities of other conventional isoforms, 
namely PKC-β, PKC-βI or PKC-βII have previously been shown to 
improve in vitro BBB integrity and function in hyperglycaemic 
settings by negating the stimulatory effects of hyperglycaemia 
on endothelial cell apoptosis, cytoskeletal remodelling, oxidative 
stress, NADPH oxidase and MMPs activities and RhoA/Rho-kinase/
MLC2 expression, activity and localisation. Inhibition of PKC-α in 
these studies has also been shown to attenuate apoptosis and 
NADPH oxidase activation in hyperglycaemic HBMEC [17,18,41]. 
Taken together with the current data, our results collectively 
indicate that activation of conventional PKC isoform i.e. 
PKC-α may augment the extent and severity of BBB damage 
in neurodegenerative conditions such as ischaemic stroke 
accompanied by uncontrolled diabetes or stress hyperglycaemia 
by concomitantly inducing various interrelated molecular 
mechanisms and that pharmacological inhibition of this isoform 
can both successfully maintain barrier function and diminish 
the incidence of secondary complications [42]. Bearing in mind 
the results of our previous studies and the necessity to develop 
efficacious therapeutic regimens that can be used as alternatives 
to the currently available sole medical therapy with recombinant 
tissue plasminogen activator after diabetic stroke, it is important 
to extend the present study to a translational model in order 
to investigate whether simultaneous suppression of multiple 
conventional PKC isoforms may exert better protection on 
cerebral barrier as compared to inhibition of a single isoform.
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